Andreu-Pérez P, et al. (2011) Protein arginine methyltransferase 5 regulates ERK1/2 signal transduction amplitude and cell fate through CRAF. Sci Signal 4, ra58 21917714

This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.

Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.

Click on the protein name to open the protein page, and on the RSD number to open the site page.

Download

T202-p - ERK1 (human) ▲

Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene Orthologous residues ERK1 (human): T202‑p, ERK1 iso2 (human): T202‑p, ERK1 iso3 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p Characterization Methods used to characterize site in vivo:  western blotting Relevant cell lines - cell types - tissues:  293 (epithelial) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes HGF increase EGF increase phorbol_ester increase MSH no change compared to control FGF1 increase FGF2 increase 5'-methylthioadenosine EGF, FGF1, FGF2, HGF augment treatment-induced increase U0126 5'-methylthioadenosine, HGF, leucine inhibit treatment-induced increase leucine HGF augment treatment-induced increase HGF PRMT5 (human), PRMT5 (mouse), PRMT5 (rat) inhibit treatment-induced increase siRNA increases EGF PRMT5 (human) augment treatment-induced increase mutant 5'-methylthioadenosine, HGF RAF1 (human) augment treatment-induced increase siRNA decreases RAF1 (human) increase R563K mutant Downstream Regulation Effect of modification (function):  intracellular localization Effect of modification (process):  signaling pathway regulation Comments:  Arginine methyltransferase 5 induced signaling for cell proliferation and differentiation

Y204-p - ERK1 (human) ▲

Modsite: HtGFLtEyVAtRWyr SwissProt Entrez-Gene Orthologous residues ERK1 (human): Y204‑p, ERK1 iso2 (human): Y204‑p, ERK1 iso3 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p Characterization Methods used to characterize site in vivo:  western blotting Relevant cell lines - cell types - tissues:  293 (epithelial) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes HGF increase EGF increase phorbol_ester increase MSH no change compared to control FGF1 increase FGF2 increase 5'-methylthioadenosine EGF, FGF1, FGF2, HGF augment treatment-induced increase U0126 5'-methylthioadenosine, HGF, leucine inhibit treatment-induced increase leucine HGF augment treatment-induced increase HGF PRMT5 (human), PRMT5 (mouse), PRMT5 (rat) inhibit treatment-induced increase siRNA increases EGF PRMT5 (human) augment treatment-induced increase mutant 5'-methylthioadenosine, HGF RAF1 (human) augment treatment-induced increase siRNA decreases RAF1 (human) increase R563K mutant Downstream Regulation Effect of modification (function):  intracellular localization Effect of modification (process):  signaling pathway regulation Comments:  Arginine methyltransferase 5 induced signaling for cell proliferation and differentiation

T185-p - ERK2 (human) ▲

Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene Orthologous residues ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p, ERK2 (cow): T185‑p Characterization Methods used to characterize site in vivo:  western blotting Relevant cell lines - cell types - tissues:  293 (epithelial) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes HGF increase EGF increase phorbol_ester increase MSH no change compared to control FGF1 increase FGF2 increase 5'-methylthioadenosine EGF, FGF1, FGF2, HGF augment treatment-induced increase U0126 5'-methylthioadenosine, HGF, leucine inhibit treatment-induced increase leucine HGF augment treatment-induced increase HGF PRMT5 (human), PRMT5 (mouse), PRMT5 (rat) inhibit treatment-induced increase siRNA increases EGF PRMT5 (human) augment treatment-induced increase mutant 5'-methylthioadenosine, HGF RAF1 (human) augment treatment-induced increase siRNA decreases RAF1 (human) increase R563K mutant Downstream Regulation Effect of modification (function):  intracellular localization Effect of modification (process):  signaling pathway regulation Comments:  Arginine methyltransferase 5 induced signaling for cell proliferation and differentiation

Y187-p - ERK2 (human) ▲

Modsite: HtGFLtEyVAtRWyr SwissProt Entrez-Gene Orthologous residues ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p, ERK2 (cow): Y187‑p Characterization Methods used to characterize site in vivo:  western blotting Relevant cell lines - cell types - tissues:  293 (epithelial) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes HGF increase EGF increase phorbol_ester increase MSH no change compared to control FGF1 increase FGF2 increase 5'-methylthioadenosine EGF, FGF1, FGF2, HGF augment treatment-induced increase U0126 5'-methylthioadenosine, HGF, leucine inhibit treatment-induced increase leucine HGF augment treatment-induced increase HGF PRMT5 (human), PRMT5 (mouse), PRMT5 (rat) inhibit treatment-induced increase siRNA increases EGF PRMT5 (human) augment treatment-induced increase mutant 5'-methylthioadenosine, HGF RAF1 (human) augment treatment-induced increase siRNA decreases RAF1 (human) increase R563K mutant Downstream Regulation Effect of modification (function):  intracellular localization Effect of modification (process):  signaling pathway regulation Comments:  Arginine methyltransferase 5 induced signaling for cell proliferation and differentiation

T203-p - ERK1 (mouse) ▲

Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene Orthologous residues ERK1 (human): T202‑p, ERK1 iso2 (human): T202‑p, ERK1 iso3 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p Characterization Methods used to characterize site in vivo:  western blotting Disease tissue studied:  melanoma skin cancer Relevant cell lines - cell types - tissues:  B16F1 (melanocyte), MEF (fibroblast) Cellular systems studied:  cell lines Species studied:  mouse Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes HGF increase EGF increase phorbol_ester increase MSH no change compared to control FGF1 increase FGF2 increase 5'-methylthioadenosine EGF, FGF1, FGF2, HGF augment treatment-induced increase U0126 5'-methylthioadenosine, HGF, leucine inhibit treatment-induced increase leucine HGF augment treatment-induced increase HGF PRMT5 (human), PRMT5 (mouse), PRMT5 (rat) inhibit treatment-induced increase siRNA increases EGF PRMT5 (human) augment treatment-induced increase mutant 5'-methylthioadenosine, HGF RAF1 (human) augment treatment-induced increase siRNA decreases RAF1 (human) increase R563K mutant Downstream Regulation Effect of modification (function):  intracellular localization Effect of modification (process):  signaling pathway regulation Comments:  Arginine methyltransferase 5 induced signaling for cell proliferation and differentiation

Y205-p - ERK1 (mouse) ▲

Modsite: HtGFLtEyVAtRWyR SwissProt Entrez-Gene Orthologous residues ERK1 (human): Y204‑p, ERK1 iso2 (human): Y204‑p, ERK1 iso3 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p Characterization Methods used to characterize site in vivo:  western blotting Disease tissue studied:  melanoma skin cancer Relevant cell lines - cell types - tissues:  B16F1 (melanocyte), MEF (fibroblast) Cellular systems studied:  cell lines Species studied:  mouse Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes HGF increase EGF increase phorbol_ester increase MSH no change compared to control FGF1 increase FGF2 increase 5'-methylthioadenosine EGF, FGF1, FGF2, HGF augment treatment-induced increase U0126 5'-methylthioadenosine, HGF, leucine inhibit treatment-induced increase leucine HGF augment treatment-induced increase HGF PRMT5 (human), PRMT5 (mouse), PRMT5 (rat) inhibit treatment-induced increase siRNA increases EGF PRMT5 (human) augment treatment-induced increase mutant 5'-methylthioadenosine, HGF RAF1 (human) augment treatment-induced increase siRNA decreases RAF1 (human) increase R563K mutant Downstream Regulation Effect of modification (function):  intracellular localization Effect of modification (process):  signaling pathway regulation Comments:  Arginine methyltransferase 5 induced signaling for cell proliferation and differentiation

T183-p - ERK2 (mouse) ▲

Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene Orthologous residues ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p, ERK2 (cow): T185‑p Characterization Methods used to characterize site in vivo:  western blotting Disease tissue studied:  melanoma skin cancer Relevant cell lines - cell types - tissues:  B16F1 (melanocyte), MEF (fibroblast) Cellular systems studied:  cell lines Species studied:  mouse Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes HGF increase EGF increase phorbol_ester increase MSH no change compared to control FGF1 increase FGF2 increase 5'-methylthioadenosine EGF, FGF1, FGF2, HGF augment treatment-induced increase U0126 5'-methylthioadenosine, HGF, leucine inhibit treatment-induced increase leucine HGF augment treatment-induced increase HGF PRMT5 (human), PRMT5 (mouse), PRMT5 (rat) inhibit treatment-induced increase siRNA increases EGF PRMT5 (human) augment treatment-induced increase mutant 5'-methylthioadenosine, HGF RAF1 (human) augment treatment-induced increase siRNA decreases RAF1 (human) increase R563K mutant Downstream Regulation Effect of modification (function):  intracellular localization Effect of modification (process):  signaling pathway regulation Comments:  Arginine methyltransferase 5 induced signaling for cell proliferation and differentiation

Y185-p - ERK2 (mouse) ▲

Modsite: HtGFLtEyVAtRWYR SwissProt Entrez-Gene Orthologous residues ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p, ERK2 (cow): Y187‑p Characterization Methods used to characterize site in vivo:  western blotting Disease tissue studied:  melanoma skin cancer Relevant cell lines - cell types - tissues:  B16F1 (melanocyte), MEF (fibroblast) Cellular systems studied:  cell lines Species studied:  mouse Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes HGF increase EGF increase phorbol_ester increase MSH no change compared to control FGF1 increase FGF2 increase 5'-methylthioadenosine EGF, FGF1, FGF2, HGF augment treatment-induced increase U0126 5'-methylthioadenosine, HGF, leucine inhibit treatment-induced increase leucine HGF augment treatment-induced increase HGF PRMT5 (human), PRMT5 (mouse), PRMT5 (rat) inhibit treatment-induced increase siRNA increases EGF PRMT5 (human) augment treatment-induced increase mutant 5'-methylthioadenosine, HGF RAF1 (human) augment treatment-induced increase siRNA decreases RAF1 (human) increase R563K mutant Downstream Regulation Effect of modification (function):  intracellular localization Effect of modification (process):  signaling pathway regulation Comments:  Arginine methyltransferase 5 induced signaling for cell proliferation and differentiation

S218-p - MEK1 (mouse) ▲

Modsite: VSGQLIDsMANsFVG SwissProt Entrez-Gene Orthologous residues MEK1 (human): S218‑p, MEK1 iso2 (human): S192‑p, MEK1 (mouse): S218‑p, MEK1 (rat): S218‑p, MEK1 (rabbit): S218‑p Characterization Methods used to characterize site in vivo:  western blotting Disease tissue studied:  melanoma skin cancer Relevant cell lines - cell types - tissues:  B16F1 (melanocyte), MEF (fibroblast) Cellular systems studied:  cell lines Species studied:  mouse Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes HGF increase 5'-methylthioadenosine HGF augment treatment-induced increase U0126 5'-methylthioadenosine, HGF, leucine inhibit treatment-induced increase leucine HGF augment treatment-induced increase DDATHF HGF augment treatment-induced increase DDATHF no change compared to control

S222-p - MEK1 (mouse) ▲

Modsite: LIDsMANsFVGTRSY SwissProt Entrez-Gene Orthologous residues MEK1 (human): S222‑p, MEK1 iso2 (human): S196‑p, MEK1 (mouse): S222‑p, MEK1 (rat): S222‑p, MEK1 (rabbit): S222‑p Characterization Methods used to characterize site in vivo:  western blotting Disease tissue studied:  melanoma skin cancer Relevant cell lines - cell types - tissues:  B16F1 (melanocyte), MEF (fibroblast) Cellular systems studied:  cell lines Species studied:  mouse Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes HGF increase 5'-methylthioadenosine HGF augment treatment-induced increase U0126 5'-methylthioadenosine, HGF, leucine inhibit treatment-induced increase leucine HGF augment treatment-induced increase DDATHF HGF augment treatment-induced increase DDATHF no change compared to control

S222-p - MEK2 (mouse) ▲

Modsite: VsGQLIDsMANsFVG SwissProt Entrez-Gene Orthologous residues MEK2 (human): S222‑p, MEK2 (mouse): S222‑p, MEK2 (rat): S222‑p, MEK2 (chicken): S220‑p, MEK2 (cow): S222‑p Characterization Methods used to characterize site in vivo:  western blotting Disease tissue studied:  melanoma skin cancer Relevant cell lines - cell types - tissues:  B16F1 (melanocyte), MEF (fibroblast) Cellular systems studied:  cell lines Species studied:  mouse Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes HGF increase 5'-methylthioadenosine HGF augment treatment-induced increase U0126 5'-methylthioadenosine, HGF, leucine inhibit treatment-induced increase leucine HGF augment treatment-induced increase DDATHF HGF augment treatment-induced increase DDATHF no change compared to control

S226-p - MEK2 (mouse) ▲

Modsite: LIDsMANsFVGTRSY SwissProt Entrez-Gene Orthologous residues MEK2 (human): S226‑p, MEK2 (mouse): S226‑p, MEK2 (rat): S226‑p, MEK2 (chicken): S224‑p, MEK2 (cow): S226‑p Characterization Methods used to characterize site in vivo:  western blotting Disease tissue studied:  melanoma skin cancer Relevant cell lines - cell types - tissues:  B16F1 (melanocyte), MEF (fibroblast) Cellular systems studied:  cell lines Species studied:  mouse Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes HGF increase 5'-methylthioadenosine HGF augment treatment-induced increase U0126 5'-methylthioadenosine, HGF, leucine inhibit treatment-induced increase leucine HGF augment treatment-induced increase DDATHF HGF augment treatment-induced increase DDATHF no change compared to control

Y1232-p - Met (mouse) ▲

Modsite: rDMyDKEyysVHNKt SwissProt Entrez-Gene Orthologous residues Met (human): Y1234‑p, Met iso2 (human): Y1252‑p, Met (mouse): Y1232‑p, Met (rat): Y1235‑p Characterization Methods used to characterize site in vivo:  western blotting Disease tissue studied:  melanoma skin cancer Relevant cell lines - cell types - tissues:  B16F1 (melanocyte), MEF (fibroblast) Cellular systems studied:  cell lines Species studied:  mouse Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes HGF increase 5'-methylthioadenosine HGF no effect upon treatment-induced increase

Y1233-p - Met (mouse) ▲

Modsite: DMyDKEyysVHNKtG SwissProt Entrez-Gene Orthologous residues Met (human): Y1235‑p, Met iso2 (human): Y1253‑p, Met (mouse): Y1233‑p, Met (rat): Y1236‑p Characterization Methods used to characterize site in vivo:  western blotting Disease tissue studied:  melanoma skin cancer Relevant cell lines - cell types - tissues:  B16F1 (melanocyte), MEF (fibroblast) Cellular systems studied:  cell lines Species studied:  mouse Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes HGF increase 5'-methylthioadenosine HGF no effect upon treatment-induced increase

T203-p - ERK1 (rat) ▲

Modsite: HDHTGFLtEyVAtRW SwissProt Entrez-Gene Orthologous residues ERK1 (human): T202‑p, ERK1 iso2 (human): T202‑p, ERK1 iso3 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p Characterization Methods used to characterize site in vivo:  western blotting Disease tissue studied:  adrenal cancer, pheochromocytoma Relevant cell lines - cell types - tissues:  hepatocyte-liver, PC-12 (chromaffin) Cellular systems studied:  cell lines, primary cultured cells Species studied:  rat Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes HGF increase EGF increase phorbol_ester increase MSH no change compared to control FGF1 increase FGF2 increase 5'-methylthioadenosine EGF, FGF1, FGF2, HGF augment treatment-induced increase U0126 5'-methylthioadenosine, HGF, leucine inhibit treatment-induced increase leucine HGF augment treatment-induced increase HGF PRMT5 (human), PRMT5 (mouse), PRMT5 (rat) inhibit treatment-induced increase siRNA increases EGF PRMT5 (human) augment treatment-induced increase mutant 5'-methylthioadenosine, HGF RAF1 (human) augment treatment-induced increase siRNA decreases RAF1 (human) increase R563K mutant Downstream Regulation Effect of modification (function):  intracellular localization Effect of modification (process):  signaling pathway regulation Comments:  Arginine methyltransferase 5 induced signaling for cell proliferation and differentiation

Y205-p - ERK1 (rat) ▲

Modsite: HTGFLtEyVAtRWYR SwissProt Entrez-Gene Orthologous residues ERK1 (human): Y204‑p, ERK1 iso2 (human): Y204‑p, ERK1 iso3 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p Characterization Methods used to characterize site in vivo:  western blotting Disease tissue studied:  adrenal cancer, pheochromocytoma Relevant cell lines - cell types - tissues:  hepatocyte-liver, PC-12 (chromaffin) Cellular systems studied:  cell lines, primary cultured cells Species studied:  rat Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes HGF increase EGF increase phorbol_ester increase MSH no change compared to control FGF1 increase FGF2 increase 5'-methylthioadenosine EGF, FGF1, FGF2, HGF augment treatment-induced increase U0126 5'-methylthioadenosine, HGF, leucine inhibit treatment-induced increase leucine HGF augment treatment-induced increase HGF PRMT5 (human), PRMT5 (mouse), PRMT5 (rat) inhibit treatment-induced increase siRNA increases EGF PRMT5 (human) augment treatment-induced increase mutant 5'-methylthioadenosine, HGF RAF1 (human) augment treatment-induced increase siRNA decreases RAF1 (human) increase R563K mutant Downstream Regulation Effect of modification (function):  intracellular localization Effect of modification (process):  signaling pathway regulation Comments:  Arginine methyltransferase 5 induced signaling for cell proliferation and differentiation

T183-p - ERK2 (rat) ▲

Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene Orthologous residues ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p, ERK2 (cow): T185‑p Characterization Methods used to characterize site in vivo:  western blotting Disease tissue studied:  adrenal cancer, pheochromocytoma Relevant cell lines - cell types - tissues:  hepatocyte-liver, PC-12 (chromaffin) Cellular systems studied:  cell lines, primary cultured cells Species studied:  rat Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes HGF increase EGF increase phorbol_ester increase MSH no change compared to control FGF1 increase FGF2 increase 5'-methylthioadenosine EGF, FGF1, FGF2, HGF augment treatment-induced increase U0126 5'-methylthioadenosine, HGF, leucine inhibit treatment-induced increase leucine HGF augment treatment-induced increase HGF PRMT5 (human), PRMT5 (mouse), PRMT5 (rat) inhibit treatment-induced increase siRNA increases EGF PRMT5 (human) augment treatment-induced increase mutant 5'-methylthioadenosine, HGF RAF1 (human) augment treatment-induced increase siRNA decreases RAF1 (human) increase R563K mutant Downstream Regulation Effect of modification (function):  intracellular localization Effect of modification (process):  signaling pathway regulation Comments:  Arginine methyltransferase 5 induced signaling for cell proliferation and differentiation

Y185-p - ERK2 (rat) ▲

Modsite: HtGFLtEyVAtRWYR SwissProt Entrez-Gene Orthologous residues ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p, ERK2 (cow): Y187‑p Characterization Methods used to characterize site in vivo:  western blotting Disease tissue studied:  adrenal cancer, pheochromocytoma Relevant cell lines - cell types - tissues:  hepatocyte-liver, PC-12 (chromaffin) Cellular systems studied:  cell lines, primary cultured cells Species studied:  rat Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes HGF increase EGF increase phorbol_ester increase MSH no change compared to control FGF1 increase FGF2 increase 5'-methylthioadenosine EGF, FGF1, FGF2, HGF augment treatment-induced increase U0126 5'-methylthioadenosine, HGF, leucine inhibit treatment-induced increase leucine HGF augment treatment-induced increase HGF PRMT5 (human), PRMT5 (mouse), PRMT5 (rat) inhibit treatment-induced increase siRNA increases EGF PRMT5 (human) augment treatment-induced increase mutant 5'-methylthioadenosine, HGF RAF1 (human) augment treatment-induced increase siRNA decreases RAF1 (human) increase R563K mutant Downstream Regulation Effect of modification (function):  intracellular localization Effect of modification (process):  signaling pathway regulation Comments:  Arginine methyltransferase 5 induced signaling for cell proliferation and differentiation